Thrombosis
Conference Coverage
Apixiban for VTE reduces subsequent hospitalizations
Major finding: Patients whose acute venous thromboembolism was treated with 6 months of apixaban were 21% less likely to have another...
Conference Coverage
Ultrasound-facilitated endovascular thrombolysis 'a game changer' in acute pulmonary embolism
Major finding: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in patients with high-risk pulmonary embolism improved right...
Conference Coverage
Off-label use of novel anticoagulants accelerates
Major finding: By the fourth quarter of 2012, 14.9% of patients with nonvalvular AF were on a novel anticoagulant. So were 13.8% of those with...
News
Tenecteplase has risks but cuts hemodynamic decompensation in pulmonary embolism
Major finding: The primary efficacy outcome – a composite of death from any cause or hemodynamic (including hemodynamic collapse) within 7 days –...
News
Dabigatran approved for VTE prevention and treatment
Conference Coverage
VIDEO: Rethink the VTE prophylaxis mantra
Conference Coverage
Apixaban provides larger medical cost savings than other NOACs
Major finding: Using apixaban instead of warfarin for stroke prevention in AF would result in an estimated medical cost savings of $1,245 per...
News
Apixaban approved for preventing DVT and pulmonary embolism after hip/knee surgery
Conference Coverage
Statins reduce recurrent thromboembolism risk
Major finding: Patients on statin therapy had an adjusted 17% lower risk of recurrent venous thromboembolism in the year following their first...
News
Genotyping adds little to optimized warfarin dosing
Major finding: Patients starting warfarin with dosing based on a formula that took into account seven clinical and demographic factors averaged 45...